![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PALM |
Gene summary for PALM |
![]() |
Gene information | Species | Human | Gene symbol | PALM | Gene ID | 5064 |
Gene name | paralemmin | |
Gene Alias | PALM1 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A024R207 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5064 | PALM | C38 | Human | Oral cavity | OSCC | 1.60e-03 | 5.41e-01 | 0.172 |
5064 | PALM | C08 | Human | Oral cavity | OSCC | 3.15e-07 | 1.83e-01 | 0.1919 |
5064 | PALM | LN38 | Human | Oral cavity | OSCC | 4.81e-04 | 9.24e-01 | 0.168 |
5064 | PALM | male-WTA | Human | Thyroid | PTC | 3.25e-34 | 3.89e-01 | 0.1037 |
5064 | PALM | PTC01 | Human | Thyroid | PTC | 3.83e-10 | 2.36e-01 | 0.1899 |
5064 | PALM | PTC03 | Human | Thyroid | PTC | 1.71e-03 | 1.81e-01 | 0.1784 |
5064 | PALM | PTC04 | Human | Thyroid | PTC | 2.69e-11 | 1.79e-01 | 0.1927 |
5064 | PALM | PTC05 | Human | Thyroid | PTC | 9.75e-24 | 6.93e-01 | 0.2065 |
5064 | PALM | PTC06 | Human | Thyroid | PTC | 6.60e-34 | 6.76e-01 | 0.2057 |
5064 | PALM | PTC07 | Human | Thyroid | PTC | 4.92e-23 | 3.95e-01 | 0.2044 |
5064 | PALM | ATC11 | Human | Thyroid | ATC | 3.82e-02 | 8.98e-01 | 0.3386 |
5064 | PALM | ATC13 | Human | Thyroid | ATC | 4.42e-31 | 7.07e-01 | 0.34 |
5064 | PALM | ATC5 | Human | Thyroid | ATC | 6.18e-44 | 7.58e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
GO:000836018 | Esophagus | ESCC | regulation of cell shape | 92/8552 | 154/18723 | 3.00e-04 | 1.81e-03 | 92 |
GO:007265918 | Oral cavity | OSCC | protein localization to plasma membrane | 169/7305 | 284/18723 | 1.69e-12 | 7.21e-11 | 169 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:010400416 | Oral cavity | OSCC | cellular response to environmental stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:002260419 | Oral cavity | OSCC | regulation of cell morphogenesis | 163/7305 | 309/18723 | 5.66e-07 | 8.19e-06 | 163 |
GO:000836016 | Oral cavity | OSCC | regulation of cell shape | 88/7305 | 154/18723 | 3.73e-06 | 4.42e-05 | 88 |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
GO:01200346 | Oral cavity | OSCC | positive regulation of plasma membrane bounded cell projection assembly | 55/7305 | 105/18723 | 3.64e-03 | 1.51e-02 | 55 |
GO:002260417 | Prostate | BPH | regulation of cell morphogenesis | 99/3107 | 309/18723 | 1.30e-11 | 9.72e-10 | 99 |
GO:000836010 | Prostate | BPH | regulation of cell shape | 47/3107 | 154/18723 | 1.27e-05 | 1.70e-04 | 47 |
GO:002260418 | Prostate | Tumor | regulation of cell morphogenesis | 102/3246 | 309/18723 | 1.25e-11 | 9.49e-10 | 102 |
GO:000836015 | Prostate | Tumor | regulation of cell shape | 51/3246 | 154/18723 | 1.42e-06 | 2.56e-05 | 51 |
GO:002260426 | Skin | AK | regulation of cell morphogenesis | 66/1910 | 309/18723 | 4.34e-09 | 3.30e-07 | 66 |
GO:000836019 | Skin | AK | regulation of cell shape | 33/1910 | 154/18723 | 2.85e-05 | 4.97e-04 | 33 |
GO:0022604111 | Skin | SCCIS | regulation of cell morphogenesis | 36/919 | 309/18723 | 1.41e-06 | 8.79e-05 | 36 |
GO:0008360110 | Skin | SCCIS | regulation of cell shape | 18/919 | 154/18723 | 5.64e-04 | 8.52e-03 | 18 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PALM | SNV | Missense_Mutation | c.55G>T | p.Ala19Ser | p.A19S | O75781 | protein_coding | tolerated(0.13) | possibly_damaging(0.56) | TCGA-69-7973-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PALM | SNV | Missense_Mutation | c.979N>C | p.Glu327Gln | p.E327Q | O75781 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
PALM | SNV | Missense_Mutation | c.761N>A | p.Ala254Glu | p.A254E | O75781 | protein_coding | tolerated(0.21) | benign(0.254) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PALM | SNV | Missense_Mutation | rs771587894 | c.335C>T | p.Ala112Val | p.A112V | O75781 | protein_coding | tolerated(0.63) | benign(0.003) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PALM | SNV | Missense_Mutation | novel | c.863N>A | p.Pro288Gln | p.P288Q | O75781 | protein_coding | deleterious(0.01) | possibly_damaging(0.775) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
PALM | SNV | Missense_Mutation | novel | c.472N>G | p.Thr158Ala | p.T158A | O75781 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PALM | SNV | Missense_Mutation | rs763907757 | c.55G>A | p.Ala19Thr | p.A19T | O75781 | protein_coding | deleterious(0.03) | possibly_damaging(0.64) | TCGA-BR-4368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |